James Mohn, MD
Cardiovascular Disease · Duluth, MNNPI 1205877941
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,613 of the $4,422 with a category attached, or 81.7%. Edwards Lifesciences accounts for 77.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $1,729 and has fallen 55.2% since, to $775 in 2025.
Across 181 payments — averaging $24.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$3K
- Medtronic$341
- Boston Scientific$323
- Shockwave Medical, Inc$183
- Abbott$101
- Abiomed$37
- plus $14 from 1 others
Across 27 payments — averaging $1560.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$42K
What the payments were for
- Grants$952%
- Travel & lodging$69316%
- Food & beverage$3,61382%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 140 | $3,424 |
| Medtronic | 14 | $341 |
| Boston Scientific | 13 | $323 |
| Shockwave Medical, Inc | 9 | $183 |
| Abbott | 3 | $101 |
| Abiomed | 1 | $37 |
| Terumo Medical Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,422 in reported general payments places this provider in the 65th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 87 | $73,783 |
| XareltoRivaroxaban | 32 | $40,333 |
| Repatha SureclickEvolocumab | 19 | $18,574 |
| Metoprolol Succinate | 235 | $4,521 |
| Atorvastatin Calcium | 141 | $1,693 |
| Losartan Potassium | 126 | $1,548 |
| Rosuvastatin Calcium | 118 | $1,404 |
| Ezetimibe | 86 | $1,145 |
| ClopidogrelClopidogrel Bisulfate | 94 | $1,016 |
| Amlodipine Besylate | 104 | $847 |
| Lisinopril | 83 | $783 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 79 | $732 |
| Carvedilol | 80 | $650 |
| Furosemide | 74 | $486 |
| Potassium Chloride | 28 | $476 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Duluth
- Christopher LatanichDuluth$128K
- Graham LohrmannDuluth$47K
- Jeffrey ChambersMinneapolis$3.2M
- Srijoy MahapatraRochester$1.2M
- Markus MeyerMinneapolis$786K
- Robert SchwartzMinneapolis$502K
- Robert VantasselMinneapolis$493K
- Charanjit RihalRochester$478K
- Amir LermanRochester$465K
- Nedaa SkeikMinneapolis$453K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.